*pharmaceuticals*

IMPACT FACTOR 4.3 | Indexed in: PubMed | CITESCORE 6.1

an Open Access Journal by MDPI

# Neuroblastoma Pathogenesis and Therapy

Guest Editor:

**Dr. Saurabh Agarwal**
Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, New York, NY 11439, USA

Deadline for manuscript submissions:
**closed (25 July 2024)**

## Message from the Guest Editor

Dear Colleagues,

Neuroblastoma is an aggressive pediatric cancer that originates from neural crest tissues of the sympathetic nervous system. High-risk neuroblastoma accounts for almost 15% of all pediatric cancer-related deaths, with overall survival rates lower than 50%. This situation become murkier when the majority of neuroblastoma patients relapse with an aggressive, refractory, and metastatic disease, with an overall survival rate of only 10%. Therefore, understanding the causes of neuroblastoma pathogenesis, relapse, and developing novel therapeutic approaches is mandatory to effectively cure neuroblastoma.

.....

In this Special Issue, we invite authors to contribute articles focusing on different aspects of neuroblastoma tumor biology, pathogenesis, developmental therapeutics, and treatment approaches. The collected articles in this Special Issue will further enhance our knowledge and understanding of the complex neuroblastoma pathogenesis and drive the development of novel therapeutic strategies.

Dr. Saurabh Agarwal
*Guest Editor*

*pharmaceuticals*

IMPACT FACTOR 4.3 | Indexed in: PubMed | CITESCORE 6.1

an Open Access Journal by MDPI

## Editor-in-Chief

**Prof. Dr. Amélia Pilar Rauter**
Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.
**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com